Aggressive treatment of performance status 1 and 2 HCC patients significantly improves survival - An Egyptian retrospective cohort study of 524 cases

Asian Pacific Journal of Cancer Prevention

Volumn 17, Issue 5, 2016, Pages 2539-2543

  Aziz, Ashraf Omar Abdel ^a   Omran, Dalia ^a   Nabeel, Mohamed Mahmoud ^a   Elbaz, Tamer Mahmoud ^a   Abdelmaksoud, Ahmed Hosni ^a   El Attar, Inas ^b   Shousha, Hend Ibrahim ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Aggressive treatment; HCC; Outcome; Performance status; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB;

ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84974633002     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2016.17.5.2539     Document Type: Article

References (25)

1. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2
2. Cabibbo G, Genco C, Di Marco V, et al (2011). Predicting survival in patients with hepatocellular carcinoma treated by transarterialchemoembolisation. Aliment Pharmacol Ther, 34, 196-204
3. European Association For The Study Of The LiverEuropean Organization For Research And Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 56, 908-43
4. Gomaa AI, Hashim MS, Waked I (2014). Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One, 9, 90929
5. Greten TF, Wang XW, Korangy F (2015). Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut, 64, 842-8
6. Hsu CY, Lee YH, Hsia CY, et al (2013). Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatol, 57,112-9
7. Hsu CY, Liu PH, Lee YH, et al (2015). Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis. Ann Surg Oncol, 22, 1324-31
8. Kim BK, Kim SU, Park JY, et al (2012). Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single-centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int, 32, 1120-7
9. Kudo M, Osaki Y, Matsunaga T, et al (2013). Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis, 31, 490-8
10. Lee YH, Hsia CY, Hsu CY, et al (2013). Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg, 37, 1348-55
11. Lee YH, Hsu CY, Huo TI (2013). Assessing liver dysfunction in cirrhosis: role of the model for end-stage liver disease and its derived systems. J Chin Med Assoc, 76, 419-24
12. Liu PH, Lee YH, Hsia CY, et al (2014). Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol, 21, 1825-33
13. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38
14. Llovet JM, Ricci S, Hilgard P, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90
15. Mittal S, El-Serag HB (2013). Epidemiology of hepatocellular carcinoma consider the population. J ClinGastroenterol 47, 2-6
16. Nuzzo G, Vauthey JN, Choti MA, et al (2013). A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg, 257, 929-937
17. Omran D A, Awad A H, Mabrouk M A, et al (2015). Application of data mining techniques to explore predictors of HCC in Egyptian patients with HCV-related chronic liver disease. Asian Pac J Cancer Prev, 16, 23-27
18. Poon RT, Fan ST, Tsang FH, Wong J (2002). Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg, 235, 466-486
19. Poon D, Anderson BO, Chen LT, et al (2009). Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol, 10, 1111-8
20. Ruzzenente A, Capra F, Pachera S, et al (2009). Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg, 13, 1313-20
21. Shaker MK, Abdella HM, Khalifa MO, El Dorry AK (2013) Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int, 33, 1601-6
22. Strickland GT, Elhefni H, Salman T, et al (2002). Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg, 67, 436-42
23. Tokushige K, Hashimoto E, Yatsuji S, et al (2010). Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol, 45, 960-7
24. Yang T, Lau WY, Zhang H, et al (2015). Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective. World J Gastroenterol, 21, 8256-61
25. Yau T, Tang VY, Yao TJ, et al (2014). Development of Hong Kong Liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterol, 146, 1691-700